c-Met/HGFR

c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .

Vabametkib: potent HGFR inhibitor, IC50 = 7 nM, halts Hs746T cell growth, used in cancer therapy.

Boditrectinib: potent TKI, anti-cancer, researches cancer, inflammation, neurodegeneration, infections.

SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)

Mifanertinib dimaleate is a potent tyrosine kinase inhibitor with antineoplastic activity .

Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor [1].

T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.

(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.

c-Met-IN-12: potent c-Met/AXL/Mer/TYRO3 inhibitor, IC50=10.6 nM, oral, anti-tumor, scaffold for selectivity enhancement.

Dalmelitinib: oral c-Met kinase inhibitor, IC50 2.9 nM, disrupts MET, AKT, ERK in cancer cells, for NSCLC research.

MK-8033 hydrochloride is an oral ATP-competitive c-Met/Ron inhibitor (IC50: c-Met 1nM, Ron 7nM), used for various cancers including NSCLC.

c-Met-IN-13: potent c-Met inhibitor (IC50 2.43 nM), exhibits anti-proliferative, cytotoxic effects; potential cancer therapy.

Emzeltrectinib is a potent tyrosine kinase inhibitor with antineoplastic activity .

c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.

MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.

(3S,4S)-Tivantinib, a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET, targets GSK3α and GSK3β—two novel enzymes implicated in the

OSI-296: potent cMET/RON inhibitor (IC50: 42/200 nM), effective in tumor models, tolerable, oral, reduces bone tumor growth.

Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].

SOMG-833 HCl is a selective inhibitor of c-MET. It acts by blocking c-MET dependent neoplastic effects and exerting antitumor activity.

(rel)-Tivantinib is a potent, highly selective inhibitor of the receptor tyrosine kinase c-MET and has additional novel targets, GSK3α and GSK3β, that are

Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.

Resencatinib is a potent tyrosine kinase inhibitor with antineoplastic activity .

Entacapone acid (AG 1290) is a selective and reversible inhibitor of catechol-O-methyltransferase(COMT).

BPI-9016M, an oral c-Met/AXL inhibitor, curbs growth and spread of lung cancer.

MET kinase-IN-2, a selective and potent MET kinase inhibitor, demonstrates oral bioavailability and exhibits an IC50 value of 7.4 nM.

MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an

Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (

TAM&Met-IN-1 inhibits AXL, MER, TYRO3 with IC50s 6.1, 13.2, 21.6 nM, respectively, for cancer research.

Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent.

c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.

c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.

Juvenile hormone B 3 (Juvenile hormone III bisepoxide) (mixture of diastereomers) is a sesquiterpenoid hormone. It can be isolated from the corpora allata (CA) of higher dipteran insects such as fruit flies and Drosophila melanogaster. This hormone exhibits anti-metamorphic activity and induces the expression of Kr-h1 by directly interacting with juvenile hormone (JH) receptors (Met and Gce). Juvenile hormone B 3 (mixture of diastereomers) is applicable in insect lethality studies.

c-Met ligand-Linker Conjugate 2 is a synthetic target protein ligand-linker complex used in the synthesis of PROTACs, such as PROTACc-Met degrader-6. PROTACc-Met degrader-6 is a c-Met PROTAC degrader that exhibits antitumor activity.

BMS-748730, also known as 4′-Hydroxy Dasatinib, is a Dasatinib metabolite.

KIN-8741 is a highly selective and orally active Type IIb c-Met inhibitor. It exhibits broad-spectrum activity against c-Met kinase mutations. KIN-8741 demonstrates antitumor activity in non-small cell lung cancer models with MET gene amplification and exon 14 deletion. It is applicable in research on c-Met-driven cancers, particularly advanced tumors harboring MET exon 14 skipping mutations and acquired resistance mutations.

KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.

D6808: selective c-Met inhibitor, IC50=2.9 nM, induces apoptosis and cell cycle arrest, for NSCLC/gastric cancer research.

3-Fluoro-desmethyl-cabozantinib-C3-O-C3-PEG-acid is a target protein ligand-linker conjugate combining a c-Met ligand with a PROTAC linker to recruit E3 ligase. It is applicable for synthesizing PROTACs, such as SJF-8240.

Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.